Fmo2-KO Mouse
Common Name
Fmo2-KO
제품 ID
S-KO-19413
Backgroud
C57BL/6JCya
품종 계통계통 ID
KOCMP-55990-Fmo2-B6J-VC
상태
이 마우스 계통을 논문에서 사용할 경우, “Fmo2-KO Mouse (카탈로그 번호 S-KO-19413)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Fmo2-KO
품종 계통계통 ID
KOCMP-55990-Fmo2-B6J-VC
유전자명
제품 ID
S-KO-19413
유전자 별칭
2310008D08Rik, 2310042I22Rik
배경
C57BL/6JCya
NCBI ID
변형 내용
Conventional knockout
염색체
Chr 1
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000045902
NCBI 전사체 ID
NM_018881
타겟 영역
Exon 4
유효 영역 크기
~0.8 kb
유전자 연구 개요
Fmo2, or flavin-containing monooxygenase 2, is involved in multiple biological processes and disease-related pathways. It has been shown to play roles in processes such as lipogenesis regulation, immune-related responses, and cell protection mechanisms. Genetic models, like gene knockout (KO) and conditional knockout (CKO) mouse models, have been crucial for studying its functions [1,3,5].
In the context of non-alcoholic fatty liver disease (NAFLD), both global and hepatocyte-specific knockout of Fmo2 in mice led to increased lipogenesis, severe hepatic steatosis, inflammation, and fibrosis. In contrast, FMO2 overexpression improved NAFL/NASH. Mechanistically, FMO2 directly interacts with SREBP1, inhibiting its translocation from the endoplasmic reticulum to the Golgi apparatus and subsequent activation, thus suppressing de novo lipogenesis [1].
In epithelial ovarian cancer, FMO2 is upregulated in tumor stroma, correlates with fibroblast activation, and predicts a worse clinical outcome. It also contributes to immune cell infiltration, especially of CD163 + macrophages [2].
In the heart, genetic deletion of FMO2 in cardiomyocytes reduced cell survival and enhanced cardiac dysfunction after ischemic injury, while cardiomyocyte-specific overexpression had a protective effect. FMO2 inhibits ER stress-induced apoptotic proteins through its disulfide bond catalytic activity [3].
In breast cancer, FMO2 is downregulated and is closely related to clinical indicators. Decreased FMO2 expression is associated with poor survival, and it may be related to immunotherapy sensitivity [4].
In post-myocardial infarction cardiac remodeling, CELF1 promotes remodeling by suppressing FMO2, and FMO2 overexpression can improve extracellular matrix deposition and cardiac remodeling [5].
In lung adenocarcinoma, circ_MACF1 upregulates FMO2 by targeting miR-421, suppressing paclitaxel resistance and malignant cellular behaviors [6].
In conclusion, Fmo2 plays essential roles in various biological processes and disease conditions. Studies using KO/CKO mouse models have revealed its significance in diseases such as NAFLD, epithelial ovarian cancer, ischemic heart disease, breast cancer, post-myocardial infarction cardiac remodeling, and lung adenocarcinoma. Understanding Fmo2 functions provides insights into disease mechanisms and potential therapeutic targets.
References:
1. Ke, Changle, Xiao, Changchen, Li, Jiamin, Wu, Rongrong, Hu, Xinyang. 2023. FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1. In Hepatology (Baltimore, Md.), 81, 181-197. doi:10.1097/HEP.0000000000000643. https://pubmed.ncbi.nlm.nih.gov/37874228/
2. Yu, Sihui, Yang, Rui, Xu, Tianhan, Wu, Sufang, Zhang, Jiawen. 2022. Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer. In Gynecologic oncology, 167, 342-353. doi:10.1016/j.ygyno.2022.09.003. https://pubmed.ncbi.nlm.nih.gov/36114029/
3. Liu, Qingnian, Huang, Jiniu, Ding, Hao, Hu, Xinyang, Wang, Jian'an. 2024. Flavin-containing monooxygenase 2 confers cardioprotection in ischemia models through its disulfide bond catalytic activity. In The Journal of clinical investigation, 134, . doi:10.1172/JCI177077. https://pubmed.ncbi.nlm.nih.gov/39480513/
4. Wu, Lichun, Chu, Jie, Shangguan, Lijuan, Cao, Mingfei, Lu, Feng. 2023. Discovery and identification of the prognostic significance and potential mechanism of FMO2 in breast cancer. In Aging, 15, 12651-12673. doi:10.18632/aging.205204. https://pubmed.ncbi.nlm.nih.gov/37963835/
5. Lai, Jun, Li, Likang, Liu, Jun, Jin, Wen, Ye, Zebing. 2025. CELF1 Promotes Post-myocardial Infarction Cardiac Remodeling Via Suppression of FMO2. In Cardiovascular toxicology, 25, 441-454. doi:10.1007/s12012-024-09951-5. https://pubmed.ncbi.nlm.nih.gov/40021568/
6. Qian, Xiaoting, Chen, Chunhua, Tong, Sanxiang, Zhang, Jun. 2023. Circ_MACF1 targets miR-421 to upregulate FMO2 to suppress paclitaxel resistance and malignant cellular behaviors in lung adenocarcinoma. In Thoracic cancer, 14, 3348-3357. doi:10.1111/1759-7714.15132. https://pubmed.ncbi.nlm.nih.gov/37814902/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
